| Title |
Cognitive Impairment in Multiple Sclerosis
|
|---|---|
| Published in |
Current Neurology and Neuroscience Reports, July 2012
|
| DOI | 10.1007/s11910-012-0294-3 |
| Pubmed ID | |
| Authors |
Jesus Lovera, Blake Kovner |
| Abstract |
Cognitive impairment (CI) is a serious complication of multiple sclerosis (MS), and the domains affected are well established, but new affected domains such as theory of mind are still being identified. The evidence that disease-modifying therapies (DMTs) improve and prevent the development of CI in MS is not solid. Recent studies on the prevalence of CI in MS among people treated with DMT, although not as solid as studies completed prior to DMT introduction, suggest that CI remains a problem even among people on DMTs and that CI occurs frequently even at the very earliest stages of MS. Functional MRI studies and studies using diffusion tractography show that the impact of lesions on cognition depends on the particular cortical networks affected and their plasticity. Cognitive rehabilitation and L-amphetamine appear promising symptomatic treatments for CI in MS, while, cholinesterase inhibitors and memantine have failed, and data on Ginkgo and exercise are limited. We need more work to understand better CI in MS and develop treatments for this serious complication of MS. |
Mendeley readers
The data shown below were compiled from readership statistics for 180 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | <1% |
| Germany | 1 | <1% |
| Brazil | 1 | <1% |
| Denmark | 1 | <1% |
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 174 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 29 | 16% |
| Student > Ph. D. Student | 23 | 13% |
| Student > Bachelor | 20 | 11% |
| Student > Doctoral Student | 19 | 11% |
| Researcher | 18 | 10% |
| Other | 33 | 18% |
| Unknown | 38 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 23% |
| Psychology | 39 | 22% |
| Neuroscience | 26 | 14% |
| Agricultural and Biological Sciences | 6 | 3% |
| Sports and Recreations | 5 | 3% |
| Other | 16 | 9% |
| Unknown | 46 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 March 2022.
All research outputs
#4,842,261
of 23,342,232 outputs
Outputs from Current Neurology and Neuroscience Reports
#282
of 932 outputs
Outputs of similar age
#33,169
of 165,569 outputs
Outputs of similar age from Current Neurology and Neuroscience Reports
#5
of 16 outputs
Altmetric has tracked 23,342,232 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 932 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 165,569 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.